NCT03767452View on ClinicalTrials.gov

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

PHASE4UnknownINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

February 29, 2020

Conditions

Peyronie's Disease

Interventions

DRUG

Xiaflex® 0.58 mg

0.25 mL injections.

Trial Locations (1)

10016

RECRUITING

Manhattan Medical Research Practice, PLLC, New York

Sponsors

Collaborators (1)

Endo Pharmaceuticals

All Listed Sponsors

collaborator

Endo Pharmaceuticals

INDUSTRY

lead

Manhattan Medical Research Practice, PLLC

INDUSTRY